

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2024/250030 A9

(43) International Publication Date
05 December 2024 (05.12.2024)

WIPO | PCT

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 31/7125 (2006.01) A61P 35/04 (2006.01)
A61K 39/39 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/032311

(22) International Filing Date:

03 June 2024 (03.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/470,653 02 June 2023 (02.06.2023) US
63/546,424 30 October 2023 (30.10.2023) US

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

13 February 2025 (13.02.2025)

(48) Date of publication of this corrected version:

03 April 2025 (03.04.2025)

(15) Information about Correction:

see Notice of 03 April 2025 (03.04.2025)

(71) Applicant: TRISALUS LIFE SCIENCES, INC.
[US/US]; 6272 West 91st Avenue, Westminster, CO 80031 (US).

(72) Inventors: KATZ, Steven, C.; 150 Fernwood Drive, East Greenwich, RI 02818 (US). COX, Bryan, F.; 3472 Big Sky Dr., Muscatine, IA 52761 (US). JAROCH, David, Benjamin; 7630 Barbara Ann Drive, Arvada, CO 80004 (US).

(74) Agent: LEE, Wan, Chieh; Haug Partners LLP, 745 Fifth Avenue, 10th Floor, New York, NY 10151 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: METHODS OF TREATING UVEAL MELANOMA LIVER METASTASES WITH A THERAPEUTICALLY EFFECTIVE COMBINATION OF ONE OR MORE CHECKPOINT INHIBITORS AND A TOLL-LIKE RECEPTOR 9 AGONIST

(57) Abstract: A method for treating uveal melanoma liver metastases in a human subject. The method comprises administering to the subject a therapeutically effective combination of one or more checkpoint inhibitors and a toll-like receptor 9 (TLR9) agonist having the structure: 5'-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3' (SEQ ID NO: 1). The one or more checkpoint inhibitors are systematically administered to the subject and the TLR9 agonist is locally administered to the liver of the subject via hepatic artery infusion at a dose sufficient to provide a concentration in the liver that is therapeutically effective in combination with the checkpoint inhibitor.



WO 2024/250030 A9